

Market Update

Healthcare Services Post-3Q24 Update

November 2024

Table of Contents

Section One — Healthcare Services Update

Healthcare Services Commentary	5
Sub-Sector Spotlight: Autism Treatments	6
Sub-Sector Spotlight: Substance Use Disorders	7
Selected Recent Transactions	8
Public Trading Comparisons	9
Healthcare Services Indices	13

Section Two — Bourne Partners

Thought Leadership	15
Bourne Partners Overview	16
Investment Bank Overview	17



Don Hooker
Director of Research
dhooker@bourne-partners.com
+1 980-414-0945



Jeremy Johnson
Senior Managing Director, Head of IB
jjohnson@bourne-partners.com
+1 704-714-8351



Aaron Olson
Managing Director, Head of Healthcare Services
aolson@bourne-partners.com
+1 917-763-8972



Xan Smith
Managing Director, Head of Sponsor Coverage
xsmith@bourne-partners.com
+1 980-372-7962



Evan Goldstein
Vice President, Healthcare Services
egoldstein@bourne-partners.com
+1 980-449-6717



Carson Riley
Vice President, Pharma Coverage
criley@bourne-partners.com
+1 615-483-9689



Bourne's Healthcare Services Expertise

Healthcare Services Sector Expertise



Industry Segments

Healthcare Services

- Post Acute Care
- Behavioral Health
- Managed Care
- Physician Practice Management
- Alternate Site



Outsourced Services

- Distribution
- Home Medical Supplies / DME
- Labs
- Pharmacy & Pharmacy Services
- Staffing



Technology & Tech-Enabled Services

- Virtual Care-Enablement
- ProviderTech
- Payor Services & Technology



Transaction Structures

- Sell/Buy-Side M&A
- Carveouts
- Alternative Financing Solutions



Healthcare Services



Pharma Services



Pharma



Consumer Healthcare

Representative Healthcare Services Transaction Activity

 Growth Recapitalization and Fund-to-Fund transfer of 	 Sale of Home Infusion Assets to A portfolio company of PPC Partners	 Advisor to Board of Directors on Strategic Alternatives	 Sale to A portfolio company of Sell-Side M&A
 Acquisition of a Majority Interest in Integrated Healthcare	 Minority Equity Investment in Exclusive financial advisor to Magellan Health	 Financial Advisor to Quorum Health on its Chapter 11 Reorganization	 Advisor to Kinderhook on its acquisition of Buy-Side M&A
 Sell-side Advisor to Brand New Day 	 Buyside Advisor to BCBS of Arizona MASSACHUSETTS	 Sale to A portfolio company of Buy-Side M&A	 Private Placement Exclusive Placement Agent

Note: Includes transactions completed at prior firms.



Section One

Healthcare Services Update

i. Healthcare Services Commentary

ii. Sub-Sector Spotlight: Behavioral Health

iii. Sub-Sector Spotlight: Infusion Therapy



Healthcare Services Sector Update



Overall healthcare services private equity deal activity remains healthy, in our view. Although deal activity has fallen from the “bubble levels” in 2021 and 2022, it is generally in-line with pre-COVID levels -- despite what has been the steepest rise in interest rates in the shortest period-of-time since the early 1980s. Behavioral health has arguably been a notable “bright spot” within healthcare services with a few recent platform deals, including *Behavioral Innovations* (acquired by Tenex Capital Management) and *Caravel Autism Health* (acquired by GTCR).

We expect that the pending Trump administration to be much more friendly to mergers and acquisitions in healthcare services. However, Trump will not be President until January 2025. In the meantime, the Department of Justice (DOJ) under President Biden, continues to push back on healthcare consolidation. In November, the DOJ filed an antitrust suit against UnitedHealth Group (NYSE: UNH) to prevent its proposed \$3.3 billion acquisition of Amedisys (NASDAQ:AMED).

In our view, **lowering healthcare costs will be an important area of focus for President-Elect Trump**. During Trump’s first term, there was a focus on price transparency regulations that required hospitals and healthcare providers to publicly disclose their prices to encourage patients to be able to “shop” for care. However, a new report by the Health and Human Services Office of Inspector General (OIG) suggests that many hospitals are still not complying with these regulations.

The Centers for Medicare and Medicaid Services (CMS) plans to cut physician payments by 2.9% in 2025, despite considerable pushback from industry groups. However, CMS will preserve popular telehealth flexibilities that were scheduled to expire at the end of 2024 and allow for advanced payments to providers participating in the Medicare Shared Savings Program (MSSP).

Media reports suggest that CVS Health has discontinued a variety of infusion services in areas like antibiotics, inotropic medications, total parenteral nutrition, and acute home infusion programs. This appears to be part of a broader corporate efficiency and restructuring strategy led by activist investor Glenview Capital.



Sources: Pitchbook, S&P Global Market Intelligence, and Company filings



Sub-Sector Spotlight: Autism Treatment Providers


We view the autism space as a vertical that will continue to benefit from favorable supply/demand dynamics, and we continue to anticipate considerable consolidation in the coming years as providers look to offer “whole-person” care for individuals with autism. Also, we see the pending renewal and passage of the *Autism Collaboration, Accountability, Research, Education and Support Act* (the Autism CARES Act) as providing significant financial visibility to the autism treatment space. This, in turn, could potentially attract more capital investment for providers.

We think that there is an emerging new consensus view that the treatment of autism needs be integrated with the treatment of other behavioral health conditions, e.g., obsessive compulsive disorder (OCD), avoidant-restrictive food intake disorder (ARFID), and school-refusal. On top of providing better care, many providers we have spoken with have highlighted that diversifying their services leads to better and more predictable financial results as well.

Advances in information technology (IT) are also a major theme that is coming up in our conversations with autism providers. Many services, such as physical/occupational therapy, cannot be fully done digitally. However, in many cases, evaluations, cognitive testing, and speech therapy testing can often be done online. Also, IT is an essential tool for tracking and documenting. Finally, IT adoption is viewed as a tool to address labor productivity (shortages).

Finally, we are hearing more about value-based reimbursement in the autism space. The autism space is ripe for value-based care, in our view. Payers are seeing troubling spending trends with the total spend per autistic individuals being multiples of neurotypical individuals. Also, providers who can develop and demonstrate more efficient and effective treatment models (e.g., “whole-person” care -- see above) can avoid the pressures of fee-for-service reimbursement by being willing to take-on two-sided risk around outcomes.

*** Please reach out if you would like to discuss, and feel free to read our updated thoughts on the autism treatment marketplace [here](#). ***



Source: Centers for Disease Control and Prevention; the Substance Abuse and Mental Health Services Administration, and Bourne Partners

Sub-Sector Spotlight: Substance Use Disorder Providers

We see the substance use disorder (SUD) space as one of the most rapidly evolving verticals within broader healthcare services. Our recent conversations with executives of SUD providers and private equity investors highlighted THREE (3) interrelated trends: 1) a rising relevance of managed care, 2) a need to prepare for greater value-based reimbursement, and 3) a growing pressure to play catch-up with information technology. In our opinion, these trends create opportunities for SUD providers to competitively differentiate themselves and pursue greater economies of scale in their operations.

We see the relevance of managed care for SUD providers increasing on the heels of new “behavioral health parity” regulations in September 2024. There seems to be a consensus view among the SUD executives that we have spoken with that the “cash pay” segment of the SUD market is going away with more patients now being covered under managed care arrangements. With greater managed care coverage will come increased pressures on traditional fee-for-service reimbursement rates, a greater focus on lower-cost modalities of treatment (e.g., outpatient, IOP, and PHP, etc.), and heightened quality and compliance oversight.


We think that SUD providers should proactively embrace value-based contracting as a way to capture the full economic value of their services. This includes proactively restructuring their operations and investing in key information technologies. In our opinion, this would include better integrating with mental health and primary care and adding lower-cost outpatient and telehealth services.

Newly released patient privacy regulations in the SUD space create a much stronger use case for information technology adoption by allowing providers to coordinate patient care in a much less burdensome way. At the same time, ongoing labor shortages have forced SUD providers to consider information technology to boost staff productivity.

*** Please reach out if you would like to discuss and feel free to read our thoughts on the substance use disorder market [here](#). ***




















With private equity looking to put capital to work in behavioral health and SUD providers, there is an increasing focus on PHP and IOP platforms While inpatient and residential treatment is appropriate for high acuity patients, several concerns exist for investors, including:

- 1) Drawing patients from a wider geographic area, necessitating broader cross-state geographic coverage
- 2) Managed care is pushing for options with shorter inpatient stays
- 3) Higher acuity businesses are struggling to retain employees
- 4) Headline risk is inherently greater for higher-acuity settings




Source: Company reports and Bourne Partners

Selected Healthcare Services Transactions

Date	Target	Acquirer	Commentary	Tags	Deal Values
Nov-2024			Provider of outsourced revenue cycle management services and software technologies	Healthcare IT	\$8,900M
Sep-2024			Adds complementary services in eating disorder care, and niche programming as well as new geographies	Behavioral Health	Undisclosed
Sep-2024			Adds economies of scale to existing revenue cycle offering as well as new patient engagement capabilities	Healthcare IT	\$365M
Jul-2024			Home infusion services and 80 ambulatory infusion centers in Michigan, Minnesota, Ohio and Wisconsin	Infusion Therapy	\$215M
Jun-2024			Independent specialty infusion pharmacy	Infusion Therapy	\$450M
Jun-2024			Tech-enabled radiology practice serving 3,300+ hospitals and other healthcare facilities	Imaging	\$773M
Jun-2024			Retailer of consumer health and wellness products focused on simplifying the tax-free healthcare market	Consumer	Undisclosed
Jun-2024			Pediatric therapy services to treat autism and/or other similar developmental disorders	Behavioral Health	Undisclosed
Jun-2024			Behavioral, speech, and occupational therapy services to children with autism and developmental disabilities	Behavioral Health	Undisclosed
Apr-2024			Risk assessment and decision analytics services for payers, providers and employers	Healthcare IT	\$11,200M


Trading Valuations: Managed Care and HMOs



Company Name	Ticker	Equity Value	Net Debt / (Net Cash)	Enterprise Value	Projected CY2025		Projected CY2025			Debt Ratio
					Revenue	Growth	EBITDA	Growth	Multiple	
Managed Care										
Centene Corporation	CNC	\$29,545	\$3,028	\$32,573	\$165,251	2.5%	\$4,552	7.5%	7.2x	0.7x
CVS Health Corporation	CVS	70,178	73,024	143,202	387,520	4.3%	16,210	11.7%	8.8x	4.5x
Elevance Health	ELV	91,423	19,282	110,705	187,289	7.0%	12,851	7.8%	8.6x	1.5x
Humana	HUM	33,155	8,262	41,417	118,760	1.6%	4,120	4.2%	10.1x	2.0x
Molina Healthcare	MOH	16,386	(2,203)	14,183	43,427	7.5%	2,266	10.3%	6.3x	-1.0x
The Cigna Group	CI	90,472	28,014	118,486	251,847	3.2%	14,367	8.2%	8.2x	1.9x
UnitedHealth Group	UNH	532,960	45,610	578,570	428,676	6.9%	42,418	10.6%	13.6x	1.1x
Average (Mean)						4.7%		8.6%	9.0x	1.5x
Average (Median)						4.3%		8.2%	8.6x	1.5x

Note: Market values as of the close of business November 15, 2024.
Source: S&P Global Market Intelligence


Trading Valuations: Home Care, Hospice and Post-Acute Care



Company Name	Ticker	Equity Value	Net Debt / (Net Cash)	Enterprise Value	Projected CY2025		Projected CY2025			Debt Ratio
					Revenue	Growth	EBITDA	Growth	Multiple	
Home Care, Hospice, and Post Acute										
AdaptHealth Corp.	AHCO	\$1,302	\$2,076	\$3,378	\$3,327	2.9%	\$686	3.1%	4.9x	3.0x
Addus HomeCare	ADUS	2,130	(173)	1,957	1,438	26.6%	\$177	28.0%	11.1x	-1.0x
Amedisys	AMED	2,948	222	3,170	2,497	6.4%	271	7.8%	11.7x	0.8x
Aveanna Healthcare	AVAH	1,121	1,425	2,545	2,102	5.0%	178	6.4%	14.3x	8.0x
BrightSpring Health Services	BTSG	3,256	2,917	6,173	12,342	10.7%	631	8.1%	9.8x	4.6x
Brookdale Senior Living	BKD	1,037	4,907	5,944	3,263	4.4%	429	11.7%	13.9x	11.4x
Chemed Corporation	CHE	8,175	(91)	8,085	2,599	7.1%	537	6.9%	15.1x	-0.2x
Encompass Health	EHC	9,961	2,652	12,613	5,825	8.9%	1,180	9.0%	10.7x	2.2x
The Ensign Group	ENSG	8,202	1,447	9,649	4,752	11.6%	542	12.0%	17.8x	2.7x
Option Care Health	OPCH	3,701	731	4,432	5,235	6.3%	449	2.0%	9.9x	1.6x
The Pennant Group	PNTG	1,086	372	1,459	813	17.9%	65	20.9%	22.3x	5.7x
Select Medical	SEM	4,800	4,378	9,178	7,365	4.4%	941	7.2%	9.8x	4.7x
U.S. Physical Therapy	USPH	1,369	136	1,505	726	9.7%	90	10.3%	16.7x	1.5x
Average (Mean)						10.5%		11.3%	13.6x	4.1x
Average (Median)						8.0%		8.6%	12.8x	2.7x

Note: Market values as of the close of business November 15, 2024.
Source: S&P Global Market Intelligence


Trading Valuations: Hospitals and Healthcare Providers



Company Name	Ticker	Equity Value	Net Debt / (Net Cash)	Enterprise Value	Projected CY2025		Projected CY2025			Debt Ratio
					Revenue	Growth	EBITDA	Growth	Multiple	
Hospitals and Healthcare Providers										
Acadia Healthcare	ACHC	\$3,444	\$1,928	\$5,372	\$3,452	9.1%	\$790	8.0%	6.8x	2.4x
Community Health Systems	CYH	500	12,095	12,595	12,626	1.0%	1,616	6.2%	7.8x	7.5x
DaVita	DVA	12,885	11,106	23,991	13,226	3.7%	2,798	4.5%	8.6x	4.0x
HCA Healthcare	HCA	85,108	41,906	127,014	74,695	5.8%	14,702	5.8%	8.6x	2.9x
Labcorp Holdings	LH	19,749	6,259	26,008	13,765	6.1%	2,383	8.9%	10.9x	2.6x
Pediatrics Medical Group	MD	1,226	463	1,689	1,942	-2.8%	229	8.9%	7.4x	2.0x
Quest Diagnostics Incorporated	DGX	18,070	6,206	24,276	10,635	8.2%	2,127	11.0%	11.4x	2.9x
RadNet	RDNT	5,898	988	6,886	1,967	8.4%	313	11.3%	22.0x	3.2x
Surgery Partners	SGRY	2,882	3,283	6,164	3,384	9.9%	568	11.7%	10.8x	5.8x
Tenet Healthcare	THC	14,550	8,777	23,327	21,393	2.9%	4,075	3.0%	5.7x	2.2x
Universal Health Services	UHS	12,997	5,001	17,997	16,700	6.1%	2,367	7.4%	7.6x	2.1x
Average (Mean)						5.3%		7.9%	9.8x	3.5x
Average (Median)						6.1%		8.0%	8.6x	2.9x

Note: Market values as of the close of business November 15, 2024.
Source: S&P Global Market Intelligence

Trading Valuations: Distributors




Company Name	Ticker	Equity Value	Net Debt / (Net Cash)	Enterprise Value	Projected CY2025		Projected CY2025			Debt Ratio
					Revenue	Growth	EBITDA	Growth	Multiple	
Healthcare Distributors										
Cardinal Health	CAH	\$28,736	\$2,297	\$31,033	\$230,192	4.0%	\$3,237	10.7%	9.6x	0.7x
Cencora	COR	47,573	1,255	48,828	321,300	7.1%	4,360	6.0%	11.2x	0.3x
Henry Schein	HSIC	9,418	2,866	12,284	13,349	3.8%	1,164	8.5%	10.6x	2.5x
McKesson Corporation	MCK	78,011	4,746	82,757	382,087	10.7%	6,249	9.5%	13.2x	0.8x
Owens & Minor	OMI	953	2,128	3,081	11,135	3.8%	607	11.9%	5.1x	3.5x
Patterson Companies	PDCO	1,811	761	2,573	6,821	3.9%	370	5.8%	7.0x	2.1x
Average (Mean)						5.5%	8.7%	9.4x	1.6x	
Average (Median)						3.9%	9.0%	10.1x	1.4x	

Note: Market values as of the close of business November 15, 2024.
Source: S&P Global Market Intelligence



Bourne Healthcare Services Indices (By Sub-Segment)



Note: Market values as of the close of business November 15, 2024.
Source: S&P Global Market Intelligence

Section Two

Bourne Partners

i. Thought Leadership

ii. Bourne Partners Overview

iii. Investment Bank Overview




Thought Leadership

Bourne Perspective

After 20+ years of exclusive industry and capital markets coverage, we know the space and we are committed to providing insights to clients. We provide cutting-edge thought leadership on all things Pharma, Pharma Services, Healthcare Services, and Consumer Health.

Through leveraging resources and insights of both Bourne Partners Strategic Capital and Investment Banking divisions, **we provide differentiated perspectives to our clients from our unique vantage point.** Our goal is to deliver heavy-hitting, timely reports in an easy-to-read format tailored specifically for executives within our industry coverage.

Conference Commentary



Industry Update Posts



Weekly Newsletter

INSIGHT

Newsletter
Recent Trends & Transactions

In This Issue

- Upcoming Events
- Bourne Insights
- Trading Comps
- Market Research
- Active Deal Contacts
- Select Transactions

Contact

Xan Smith
PE Coverage & Origination

Jeremy C. Johnson
Head of Investment Banking

Don Hooker, CFA
Head of Research

About

Research

Marketplace Deep Dive Reports



White Papers

BOURNE BRIEF

Incremental Insights into Clinical Trial Site Networks

Key Take-Aways from the SCRS Global Site Solutions Summit

The Bourne Partners team attended the Society of Clinical Research Sites (SCRS) 2024 Global Site Solutions Summit in Paris this week to get incremental visibility into the trends impacting the clinical trial site space. We continue to expect ongoing consolidation of clinical trial sites into larger site networks (or site management organizations) in the coming years. In our view, the rise of the site networks is bringing much-needed experience of scale to an otherwise fragmented universe of standalone clinical trial sites.

For more discussion, see our recent research report: [Global Trial Site Networks: Market Research Update](#) (September 2024).

Take Away 1:

A Challenging Environment for Standalone Clinical Trial Sites

We see the clinical trial site landscape as overly fragmented, mostly consisting of single standalone sites that lack the economics of scale to absorb rising labor costs, the increasing burdens of information technology adoption, and the administrative challenges of supporting more complex clinical trials. Our thesis was reinforced by our attendance at the Summit this year. Data from the SCRS Annual Site Landscape Survey (released at the Summit) confirmed that standalone sites are indeed struggling financially. A third of the sites in the survey reported lower than one-year profit margins in each revenue band. And, half (50%) of clinical trial sites in the survey reported having less than three months of operating capital (cash on hand) in the bank. Refer to Figure 1.

Figure 1: Many Standalone Clinical Trial Sites Are Operating on "Shoe String" Budgets

Clinical Trial Sites: Healthy Observations

- 55% of sites reported a net profit margin of the last 12M
- 55% of sites reported a decreasing profit margin (last 12M vs 24M)
- 55% of sites have more than a third of their operating revenue received in 90 days

Trial Sites: Number of Months of Operating Capital

Half (50%) of sites have less than three months of operating capital (cash on hand) in the bank.

Also, almost a third (33%) of sites reported lower operating capital over the past year.

More specifically, we heard three common challenges at the panel discussions at the Summit that seem to be exacerbating the financial struggles of standalone sites. First, more often than not, sites are not getting fully funded by sponsors for their patient recruitment costs. This has resulted in many sites having to dip into their own cash reserves. We think site networks are better able to pool advertising and marketing resources and extend outreach campaigns across broader geographies. So, we suspect this has been more of a problem for standalone sites. A second area of financial pressure is time-consuming and costly screen fails, e.g., situations when a site goes through the entire screening process for a patient only to find an exclusionary data point that disqualifies the patient. A simple fix here would be to negotiate payments on a "per procedure" basis. Finally, payment schedules continue to be suboptimal. A solid majority of clinical trial sites (72%) prefer monthly payment schedules, but only 38% are able to negotiate them. Adding to this, withholding rates remain high, which is resulting in sites not getting paid for a portion of their work for several years (often after the study is closed). Refer to Figures 2 and 3.

September 30, 2024

BOURNE PARTNERS



Bourne Partners Overview

Bourne Partners is a leading healthcare-focused investment bank headquartered in Charlotte, NC. Since 2001, Bourne has been offering a unique perspective and unmatched expertise while remaining highly focused on fulfilling the needs of established middle market healthcare companies across the globe

Our Passion

*“Working with **great people** and **great companies** to achieve **extraordinary results.**”*

Highly-focused Firm



PHARMA & LIFE SCIENCES



PHARMA SERVICES



PHARMACY SERVICES



HEALTHCARE SERVICES

Comprehensive Healthcare Service Offering

Mergers & Acquisitions		Capital Raising	
<i>Sell-Side Assignments</i>	<i>Buy-Side Assignments</i>	<i>Debt</i>	<i>Equity</i>
<i>Company & Product Focus</i>	<i>\$50M to \$1B+ Enterprise Value</i>	<i>Alternative Options</i>	<i>\$20M to \$1B+ Capital Raises</i>
Business Development Services		Strategic Initiatives & Consulting	
<i>Partnerships in U.S. / Abroad</i>	<i>In and Out-Licensing</i>	<i>Strategy & Management</i>	<i>Sales/Marketing, Operations</i>

Value-add Advisors With A Global Reach

\$15B+
Successful Transactions

6
Continents

20+
Year Track Record





Investment Banking Overview

Bourne Partners Investment Banking provides investment banking services within the healthcare and life sciences sectors for external clients as well as our portfolio companies.

Value Beyond the Deal

Total Perspective

Experience advising, investing in, building, operating, buying, and selling companies
 Unmatched 360° perspective for every project

Uncompromised Service

Direct involvement of senior management through the process
 High level of attention regardless of transaction value

Global Reach

Experience working with companies around the globe
 Extensive network of potential international buyers

Focus Areas



Select Recent Tombstones

 has been acquired by 	 has sold its consumer CDMO operations to 	 has been acquired by 	 has been acquired by 	 has been acquired by 	 has been recapitalized by
------------------------------	--	------------------------------	------------------------------	------------------------------	-----------------------------------

Partners, Sponsors, and Lenders



Recent Clients & Counterparties





550 South Caldwell Street, Suite 900
Charlotte, NC 28202
+1 704.552.8407

